Table 1 Baseline clinical characteristics of patients.

From: Addition of metformin to anti-PD-1/PD-L1 drugs activates anti-tumor immune response in peripheral immune cells of NSCLC patients

Variable

Patientsa (n = 18)

Age, years (mean ± SD)

70.56 ± 7.21

 Sex (n, %)

 

  Male

9 (56.25%)

  Female

7 (43.75%)

 Clinical stage (n, %)

 

  III

2 (12.5%)

  IV

14 (87.5%)

 PD-L1 expression (n, %)

 

  < 1%

9 (56.25%%)

  > 1%

7 (43.75%%)

  1. Data are reported as number (n), frequency (%) or mean ± SD: standard deviation. aPatients race/ethnicity was White/Italian.
Back to article page